首页 > 市场调查报告书 > 製药

生物标记

市场调查报告书

商品编码

1548852

数位生物标记市场规模、份额和增长分析：按类型、临床实践、最终用途、地区 - 行业预测，2024-2031 年

Digital Biomarkers Market Size, Share, Growth Analysis, By Type, By Clinical Practice, By End-Use, By Region - Industry Forecast 2024-2031

出版日期: 2024年08月30日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球数位生物标记市场规模约24.3亿美元，从2023年的29.6亿美元成长到2031年，预测期间（2024-2031年）复合年增长率为21.9%，预计将达到144.4亿美元。

由于健康相关行动应用程式、连网型数位设备、智慧型手机使用量的增加以及新型可穿戴设备的采用，数位生物标记市场预计将显着增长。这些进步正在提高患者和医生对心血管健康的了解，特别是透过检测预示心臟病早期阶段的心律不整。这种日益增长的兴趣正在加速数位生物标记市场的扩张。这种增长得到了推动数位生物标记研究的投资和资金筹措增加的进一步支持。医疗技术公司也利用数位生物标记技术来对抗 COVID-19 大流行，为市场扩张做出贡献。例如，Medopad 正在与全球合作伙伴合作，根据呼吸指标检验数位生物标记，以识别高风险的 COVID-19 患者，以及流行病如何对市场产生积极影响。此外，数位生物标记物超越了传统的智慧型手錶和活动追踪器。领先的製药公司正在与创新的数位健康新兴企业合作，以加强数位生物标记解决方案的采用和开发，预计这将进一步推动市场成长。由于 COVID-19 大流行带来的挑战，各国政府也对基于数位生物标记的治疗表现出了兴趣。儘管有潜在的好处，但资料隐私、可靠性、检验问题和缺乏开放原始码资料等挑战可能会阻碍市场成长。然而，日益激烈的竞争和这些技术的广泛采用预计将在预测期内解决这些障碍。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

ActiGraph LLC（US）
AliveCor Inc.（US）
Koneksa（US）
Altoida Inc.（US）
Amgen Inc.（US）
Biogen Inc.（US）
Empatica Inc.（US）
IXICO plc（UK）
Adherium Limited（New Zealand）
Neurotrack Technologies, Inc.（US）
Aural Analytics（US）
Huma（UK）
Sonde Health, Inc.（US）
Clario（US）
Imagene AI（Israel）
Brainomix（UK）
Kinsa Inc.（US）
Solve.Care（Estonia）
HIVE Blockchain Technologies Ltd.（Canada）
Encrypgen（US）
Sana Benefits（US）
Healthereum（US）
Patientory（US）

简介目录

Product Code: SQMIG35G2218

Global Digital Biomarkers Market size was valued at around USD 2.43 billion in 2022 and is expected to rise from USD 2.96 billion in 2023 to reach a value of USD 14.44 Billion by 2031, at a CAGR of 21.9 % over the forecast period (2024-2031).

The market for digital biomarkers is expected to experience significant growth, driven by the rapid adoption of health-related mobile applications, connected digital devices, increased smartphone usage, and the introduction of new wearables. These advancements are enhancing patients' and doctors' understanding of cardiovascular health, particularly by detecting arrhythmias that can signal early stages of heart disease. This surge in interest is accelerating the expansion of the digital biomarkers market. The growth is further supported by increased investments and funding aimed at advancing research into digital biomarkers. Health technology companies have also leveraged their digital biomarker technologies to address the COVID-19 pandemic, contributing to market expansion. For example, Medopad is working with global partners to validate digital biomarkers for respiratory indicators and identify high-risk COVID-19 patients, illustrating how the pandemic is positively impacting the market. Moreover, digital biomarkers extend beyond traditional smartwatches and activity trackers. Major pharmaceutical companies are collaborating with innovative digital health startups to enhance the adoption and development of digital biomarker solutions, which is anticipated to further drive market growth. Governments are also showing interest in digital biomarker-based treatments due to the challenges posed by the COVID-19 pandemic. Despite the potential advantages, there are challenges such as data privacy, reliability, validation issues, and a shortage of open-source data that could hinder market growth. However, increased competition and broader adoption of these technologies are expected to address these obstacles during the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Digital Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Digital Biomarkers Market Segmental Analysis

The Biomarker Market is segmented based on type, clinical practice, therapeutic area, end users and region. Based on type, the market is segmented into Wearable, Mobile based Applications, Sensors, and others. Based on clinical practice, Diagnostic digital biomarkers, Monitoring digital biomarkers, Predictive and Prognostic digital biomarkers, Others. Based on therapeutic area, the market is segmented into Cardiovascular and metabolic disorders (CVMD), Respiratory disorders, Psychiatric disorders, Sleep & Movement Disease, Neurological disorders, Musculoskeletal disorders, Others (Diabetes, Pain Management). Based on end -users, the market is segmented into healthcare companies, Healthcare Providers, Payers, Others (Patient, caregivers). Based on region, North America, U.S., Canada, Mexico, Europe,UK, Spain, Italy, France, Denmark and others.

Drivers of the Global Digital Biomarkers Market

The increasing prevalence of chronic conditions like diabetes, cardiovascular diseases, and cancer is fueling the demand for digital biomarkers. These technologies play a crucial role in the early detection and effective management of such diseases. Digital biomarkers offer valuable insights that aid in identifying health issues at an earlier stage, which is essential for improving patient outcomes and managing chronic diseases more efficiently.

Restraints in the Global Digital Biomarkers Market

The absence of well-defined regulatory guidelines for digital biomarkers is impeding market growth by creating uncertainty for both investors and manufacturers. This lack of clarity makes it challenging for stakeholders to navigate the regulatory landscape, which can deter investment and slow the development of new technologies. The uncertainty surrounding regulatory requirements for digital biomarkers also affects the market's progress. Without clear guidelines, companies face difficulties in ensuring compliance and bringing new products to market, which in turn hampers the overall expansion of the industry.

Market Trends of the Global Digital Biomarkers Market

Wearables and mobile health apps are gaining widespread adoption among both consumers and healthcare providers due to their ability to facilitate continuous and remote patient monitoring. This growing trend is significantly contributing to the expansion of the digital biomarkers market. These devices generate vast quantities of data, which is instrumental in the development of digital biomarkers. As more people use wearables and health apps, the volume of data available for creating and refining digital biomarkers increases, further fueling market growth.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors of The Market
Degree Of Competition
Top Investment Pockets
Market Attractive Index
Ecosystem Mapping
Technology Analysis
Cost Analysis
Market Trend Analysis
Competition Analysis
Supply chain analysis
Investment Analysis
Application-Specific Analysis
Patent analysis
Trade analysis
Case study analysis

Digital Biomarkers Market by Type

Wearable
Mobile based Applications
Sensors
Others

Digital Biomarkers Market by Clinical Practice

Diagnostic digital biomarkers
Monitoring digital biomarkers
Predictive and Prognostic digital biomarkers
Others

Digital Biomarkers Market by Therapeutic Area

Cardiovascular and metabolic disorders (CVMD)
Respiratory disorders
Psychiatric disorders
Sleep & Movement Disease
Neurological disorders
Musculoskeletal disorders
Others
- Diabetes
- Pain Management

Digital Biomarkers Market by End-Use

Healthcare companies
Healthcare Providers
Payers
Others
- Patient
- Caregivers

Digital Biomarkers Market by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

ActiGraph LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AliveCor Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koneksa (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Altoida Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Empatica Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IXICO plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adherium Limited (New Zealand)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurotrack Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aural Analytics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Huma (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sonde Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clario (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Imagene AI (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Brainomix (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kinsa Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Solve.Care (Estonia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
HIVE Blockchain Technologies Ltd. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Encrypgen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sana Benefits (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Healthereum (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Patientory (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments